NRG Clinical Trials Development Core Abstract The NRG Oncology (NRG) Clinical Trials Development Core (Core) provides the scientific leadership and infrastructure necessary to support the group's research activities and initiatives. NRG has a robust facility for clinical trials development, led by physician-investigators, statisticians, and administrative directors who possess an outstanding quantity and quality of knowledge and expertise in designing and directing complex, multicenter clinical trials that reflect the specific aims of the group. The Core works closely with the NRG's Statistics and Data Management Center, the NRG Data Monitoring Committee (DMC), and the NRG Administrative Core in soliciting, reviewing, approving, and developing prospective clinical trials. The program is committed to developing clinical trials that are congruent with NRG's and NCI's mission to implement high-quality clinical and translational trials (primarily late phase trials) in a timely manner. To that end, the Core investigators and staff work closely with NCI-CTEP, the NCTN's centralized functions (e.g., CTSU, CIRB) and the other NCTN Groups. Patient advocates and attention to diversity are included in the Core's functions. NRG's clinical trials development program is led by its Research Strategy Committee, whose members are internationally recognized chairs and vice-chairs of NRG's cancer disease site and other scientific committees who have great experience in institutional and network group research. The leaders and core members of these committees understand the importance of protocol development, new investigator training/mentorship, trial conduct, completion and timely analysis and publication of study results. These physician investigators and the Core administrative staff are well aligned with the overall mission of the NCTN and the continued success of NRG Oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180868-06
Application #
9627155
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-16
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Bertagnolli, Monica M; Blaney, Susan M; Blanke, Charles D et al. (2018) Current Activities of the Coalition of Cancer Cooperative Groups. J Natl Cancer Inst :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Dignam, James J; Hamstra, Daniel A; Lepor, Herbert et al. (2018) Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol :JCO1800154
Blumenthal, Deborah T; Won, Minhee; Mehta, Minesh P et al. (2018) Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro Oncol 20:966-974
Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Tew, William P; Sill, Michael W; Walker, Joan L et al. (2018) Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:257-263
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Richardson, Debra L; Sill, Michael W; Coleman, Robert L et al. (2018) Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 4:196-202
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11

Showing the most recent 10 out of 357 publications